In section Market Quotes

CG Oncology Shares Jump 20% on Bladder Cancer Trial Results

A 68% reduction in recurrence risk in a Phase 3 trial sent CG Oncology shares sharply higher Monday, after the company said its bladder cancer treatment met the study’s primary endpoint. The stock rose 20% to $89.30, and has more than doubled year to date.

CG Oncology Shares Jump 20% on Bladder Cancer Trial Results

The trial tested adjuvant intravesical cretostimogene grenadenorepvec against a control arm in certain patients with non-muscle invasive bladder cancer following complete tumor resection. CG Oncology described the improvements as statistically significant and clinically meaningful.

The company said the treatment was generally well tolerated, with safety results consistent with those in previous studies. No treatment-related adverse events of grade 3 or greater were reported, according to CG Oncology.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!